Biosimilars Market Demand, Growth, Opportunities, Analysis of Top Key Player and Forecast to 2025 - PowerPoint PPT Presentation

View by Category
About This Presentation
Title:

Biosimilars Market Demand, Growth, Opportunities, Analysis of Top Key Player and Forecast to 2025

Description:

The scope of the Biosimilars Market report includes a detailed study of global and regional markets and Identify the growth segment and apportunity in the industry. – PowerPoint PPT presentation

Number of Views:3

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Biosimilars Market Demand, Growth, Opportunities, Analysis of Top Key Player and Forecast to 2025


1
Global Biosimilars Market
  • Drivers, Restraints, Potential Growth
    Opportunities, Product Size, Application
    Estimation, Vendor Competitive Landscape, Trends
    and Forecast 2018-2025

Single Use License US 4500
Request Sample
2
Global Biosimilars Market
  • The global biosimilars market size was
    anticipated to reach xx billion supported by a
    CAGR of xx over the forecast period. Occurrence
    of large number of chronic disorders and
    affordability of biosimilar drugs are the main
    factors participating in the growth of the global
    biosimilars market.
  • Biosimilar products are similar to their
    accredited products on the basis of biological
    activity, efficacy, and safety and quality
    characteristics. An occurrence of chronic
    disorders such as cancer, anemia, diabetes,
    autoimmune diseases, kidney failure, rheumatoid
    arthritis, infectious diseases and deficiency of
    growth hormones is projected to fuel the global
    biosimilars industry in the coming years.
  • Specialty biologics is the biggest factor for
    pharmaceutical cost growth in the market. In the
    U.S., as per research around nine patents for top
    20 retailing biologics are supposed to expire by
    2020. However, biosimilars are less expensive
    than the original drugs hence, more usage of
    biosimilars will lead to cost savings. The first
    biosimilar was accepted by European Medicines
    Agency in 2006 and has approved out of 40
    biosimilars.
  • Food and Drug Administration (FDA) confirmed
    their first biosimilar through Zarxio, which is a
    biosimilar of filgrastim used in treating low
    blood neutrophils. Overall, total 11 biosimilars
    were approved by FDA out of which only 3
    biosimilars are launched.
  • Browse the complete report on _at_
    https//www.adroitmarketresearch.com/industry-repo
    rts/biosimilars-market

3
Global Biosimilars Market
  • Product segment in the biosimilars market
    consists of Erythropoietin, Human Growth Hormone,
    Insulin, Monoclonal Antibodies, Colony
    Stimulating Factors, Interferon and more.
    Biosimilars market is divided into oncology
    diseases, growth hormone deficiency, blood
    disorders, autoimmune and chronic disorders.
  • Use of biosimilars in the treatment of blood
    disease is the maximum revenue making segment.
    Increase in use of biosimilars for treating
    several diseases is helping to scale up the
    global biosimilar market size.
  • The biopharmaceutical industry is dependent on
    advanced technologies used in several processes
    of manufacturing and development. Some of the
    important technologies involved in biosimilars
    are Recombinant DNA technology, Monoclonal
    Antibodies Technology, Chromatography, Nuclear
    Magnetic Resonance Technology, Bioassay, Western
    Blotting, and Mass Spectrometry.
  • Bioassay and Monoclonal Antibodies technology
    are the most important technologies used for
    validation and development of global biosimilars
    market share.
  • Pharmaceutical companies are mainly focusing on
    development of biosimilars and they are accepting
    clinical trials strategies and approval.

4
Global Biosimilars Market
  • Approval and clinical trials strategies are the
    main factors in the biosimilar market globally.
    Companies such as Merck Serono, Celltrion and
    Sandoz are looking for approvals across the
    world. These companies are branches of global
    industries such as Novartis and Merck, which
    allows investing in biosimilar market. 
  • The plans accepted by manufacturers in an
    integrated manner where all clinical trials
    conducted for approvals and commercialization.
    Joint venture, License, product launch,
    partnership are the policies accepted by
    companies who had got permission from the
    authorities and have successfully copied the
    original drugs. Thus, development of biosimilars
    by manufacturers are increasing the growth of the
    global biosimilars industry.
  • Benefits of the global biosimilars market
  • Cost of treatment is less by using biosimilars
    rather than using the biological drug.
  • The profit margin of operating original
    biological drug is around 30, but for operating,
    the biosimilar product, profit margin is around
    40.
  • As license of original product expires thus,
    opportunities for a generic version of
    biopharmaceutical products is very large.
  • Funding is easily available across the world.

5
Global Biosimilars Market
  • Regional Overview
  • Geographically, global biosimilar industry is
    divided into Europe, South America, North
    America, Asia Pacific and Middle East Africa.
    North America holds the largest share of the
    global biosimilar market. The market of North
    America is mainly driven due to the presence of
    research laboratories, such as Amgen, Sandoz,
    Teva Pharmaceuticals and many more. Due to the
    development of biotechnology companies, Asia
    Pacific is anticipated to experience growth over
    the forecast period.
  • Key Players
  • Companies involved in expanding the global
    biosimilar market size are Teva Pharmaceutical
    Industries Ltd., Amgen Inc., Sandoz
    International, Hoffmann-La Roche Ltd., Dr.
    Reddys Laboratories Ltd., Pfizer Inc., Mylan,
    Biocon, and Samsung Bioepis.
  • Purchase a single user copy of the global
    Biosimilars market report _at_ https//www.adroitmark
    etresearch.com/researchreport/purchase/72

6
About Us
  • Adroit Market Research is an India-based business
    analytics and consulting company. Our target
    audience is a wide range of corporations,
    manufacturing companies, product/technology
    development institutions and industry
    associations that require understanding of a
    markets size, key trends, participants and
    future outlook of an industry. We intend to
    become our clients knowledge partner and provide
    them with valuable market insights to help create
    opportunities that increase their revenues. We
    follow a code Explore, Learn and Transform. At
    our core, we are curious people who love to
    identify and understand industry patterns, create
    an insightful study around our findings and churn
    out money-making roadmaps. Our analysts have
    tracked high growth markets in chemicals
    materials, healthcare pharmaceuticals,
    semiconductor electronics, energy power, food
    retail, consumer goods, technology, and
    machinery equipment sectors across the world to
    identify new opportunities, potential customers,
    prepare go-to-market (GTM) strategies, identify
    segments for revenue growth for companies, and
    many more.
  • US Headquarters3131 McKinney Ave Ste 600
    Dallas, TX 75204 ,U.S.A 
  • Phone 1 (214) 884-6068
  • Email sales_at_adroitmarketresearch.com
About PowerShow.com